103898-38-0
| 中文名称 | 103898-38-0 |
|---|---|
| 中文同义词 | 化合物 T16897 |
| 英文名称 | SM 6586 |
| 英文同义词 | SM 6586;3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-[3-[[methyl(phenylmethyl)amino]methyl]-1,2,4-oxadiazol-5-yl]-4-(3-nitrophenyl)-, methyl ester;SM6586,SM 6586 |
| CAS号 | 103898-38-0 |
| 分子式 | C26H27N5O5 |
| 分子量 | 489.52 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 103898-38-0.mol |
| 结构式 |  |
103898-38-0 性质
| 熔点 | 127-128 °C |
|---|---|
| 沸点 | 624.0±65.0 °C(Predicted) |
| 密度 | 1.270±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 酸度系数(pKa) | 5.10±0.50(Predicted) |
SM-6586 是一种 calcium channel 的拮抗剂，同时能够抑制 Na+/H+ 和 Na+/Ca2+ exchange transport，主要用于研究脑血管疾病和高血压等疾病。
In SM-6586-treated spontaneously hypertensive rats, the survival rate after bilateral common carotid artery ligation is higher, the brain water content is lower, and the ATP level is higher and lactate level. In focal ischemia models, the SM-treated group shows a reduction of T1 relaxation time. The brain water content is significantly decreased in the SM-treated group.